IMP-321
Non-Small Cell Lung Carcinoma
Immutep S.A.S.protein_peptidePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 95/ 100
Competitive context
1127 Active assets in the Non-Small Cell Lung Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Necitumumab Jonsson Comprehensive Cancer Center | Phase 3 | BBB |
Glumetinib Shanghai JMT-Bio Inc. | Phase 3 | BBB |
Veliparib AbbVie | Phase 3 | BBB |
d-0316 Betta Pharmaceuticals Co., Ltd. | Phase 2/3 | BBB |
Icotinib The First Affiliated Hospital of Guangzhou Medical University | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
IMP-321 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →